CD73/NT5E在胶质母细胞瘤中的研究进展  

Research progress of CD73/NT5E in glioblastoma

作　　者：邵将 李琳[1] 郭岩松 孙程圆 温稀超 郑克彬[1] 史彦芳[1] SHAO Jiang;LI Lin;GUO Yansong;SUN Chengyuan;WEN Xichao;ZHENG Kebin;SHI Yanfang(Department of Neurosurgery,the Affiliated Hospital of Hebei University,Baoding 071000,China)

机构地区：[1]河北大学附属医院神经外科,河北保定071000

出　　处：《实用医学杂志》2024年第3期428-431,438,共5页The Journal of Practical Medicine

基　　金：河北省自然科学基金项目(编号:H2016201238);2019政府资助临床医学优秀人才培养项目(编号:361007);河北大学医学学科重点项目(编号:2020A11);河北大学附属医院2019年度院内基金项目(编号:2019Z003)。

摘　　要：胶质瘤是最常见的原发性中枢神经系统肿瘤,主要来源于神经胶质细胞,具有侵袭性强、易复发、预后差的特点。胶质母细胞瘤是恶性程度最高的高级别胶质瘤,临床治疗方法为手术切除为主,辅以放化疗及电场治疗等综合治疗,但治疗效果并不令人满意。CD73是一种与腺苷代谢相关的新型免疫检查点,近年来随着肿瘤免疫治疗领域的迅速发展,发现CD73可以通过抑制抗肿瘤免疫反应和促进血管生成来促进肿瘤进展。本文系统综述了CD73的作用机制,并讨论其在胶质瘤中的生物学作用及应用,旨在为胶质瘤患者的治疗提供潜在的治疗方案。Glioma is the most common primary central nervous system tumor,mainly derived from glial cells,with strong invasiveness,easy recurrence,and poor prognosis.Glioblastoma is a high-grade glioma with the highest degree of malignancy.The clinical treatment method is mainly surgical resection,supplemented by compre⁃hensive treatment such as radiotherapy,chemotherapy,and electric field therapy,but the treatment effect is not satisfactory.In recent years,with the rapid development of the field of tumor immunotherapy,CD73 is a novel immune checkpoint related to adenosine metabolism,which can promote tumor progression by inhibiting anti⁃tumor immune responses and promoting angiogenesis.This article systematically reviews the mechanism of action of CD73 and discusses its biological role and application in glioma,aiming to provide potential treatment options for glioma patients.

关 键 词：胶质母细胞瘤 CD73/NT5E 腺苷 免疫检查点 免疫治疗 

分 类 号：R739.41[医药卫生—肿瘤]